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This year, the Albert Lasker Basic Medical Research Award will be shared by Peter Walter and
Kazutoshi Mori for discoveries revealing the molecular mechanism of the unfolded protein
response, an intracellular quality control system that detects harmful misfolded proteins in the
endoplasmic reticulum and then signals the nucleus to carry out corrective measures.Our cells communicate with their envi-
ronment using secreted proteins and
proteins displayed on the cell surface.
In order to reach their destinations,
these proteins must enter the secretory
pathway via insertion into the endo-
plasmic reticulum (ER), where they are
folded and matured. Initially, the UPR
was all about stress and how our cells
handle assaults that result in the inca-
pacity of the ER to fold proteins. Today,
it is recognized that the UPR works
normally as a homeostat that keeps the
cell’s protein folding capacity balanced
with its needs and is especially important
in cells that professionally secrete pro-
teins such as immunoglobulin-secreting
plasma cells.
The prologue to the discovery of the
UPR begins with the scientific enquiry
into what happens to cells when they are
stressed with heat. The answer is that
nearly all cell types from yeast to mam-
mals transcriptionally upregulate a set of
genes encoding heat-shock proteins
(HSP). When cells are stressed under
conditions such as increased tempera-
ture, many proteins are unstable and
become misfolded. HSPs bind to dena-
tured proteins that have a tendency to
form insoluble aggregates and help solu-
bilize them. The first indication that this
process also occurs in the secretory
pathway appeared in the late 1980s,
with an observation from Hugh Pelham’s
laboratory. During the course of isolating
cDNA clones for HSPs, they discovered
that one HSP homolog contained a signal
peptide targeting it to be localized within
the ER. This protein had previously beenidentified as both a glucose-regulated
protein (GRP) and an immunoglobulin
heavy-chain binding protein (BiP). Putting
two and two together, HSPs were subse-
quently shown to bind to misfolded pro-
teins in the cytoplasm/nucleus. In an
analogous way, BiP (GRP78) was shown
to bind to incompletely folded proteins in
the secretory pathway. In addition, BiP
was released from its binding partners
by the addition of ATP, similar to the way
HSPs are released from their substrates.
Therefore, BiP seemed to function in the
ER in the same manner as heat-shock
proteins in the cytoplasm/nucleus. Thus,
the conceptual framework was estab-
lished for differentiating between the
heat-shock effect in the cytoplasm medi-
ated by the heat-shock proteins and the
unfolded protein response in the ER
mediated by the GRPs. This body of
work collectively birthed the UPR and
set the stage for Peter Walter at the Uni-
versity of California, San Francisco (USA)
and Kazutoshi Mori at Kyoto University
(Japan) to pursue the molecular mecha-
nisms responsible for these phenomena.
The First Steps
Walter and Mori independently took
advantage of the yeast, Saccharomyces
cerevisiae, as a model system to begin
studying the UPR. Although their ap-
proaches were different, they consistently
arrived at the same conclusions. In-
stances in which key findings are inde-
pendently discovered and confirmed
by separate groups are rare and result
in an accelerated pace of discovery. This
was the case with Walter and Mori.Cell 158, SepThe story begins in the early 1990s,
when Kazutoshi Mori, a postdoctoral
fellow in the laboratories of Mary-Jane
Gething and Joseph Sambrook, initiated
studies on the S. cerevisiae KAR2 (BiP)
gene and defined a 22 bp UPR promoter
element (UPRE) that stimulates the
activity of a heterologous promoter in
response to the presence of unfolded
proteins in the ER (Mori et al., 1992). Using
this information as the basis for a genetic
screen, they identified a class of mutants
unable to respond to the presence of
unfolded proteins in the ER. In these
studies, they describe the ERN1 gene,
which encodes a 1115 amino acid
transmembrane protein belonging to the
CDC28/cdc2+ family of serine threonine
kinases (Mori et al., 1993). Concomitantly,
Peter Walter’s laboratory used the UPRE
defined by Mori in a genetic screen of
their own design with a different readout
and isolated mutants that fail to induce
KAR2 mRNA in response to unfolded
proteins in the ER. Surprisingly, they had
identified the same gene as Mori but re-
tained the previously reported name,
IRE1 (Cox et al., 1993). This work repre-
sented an important clue because IRE1
was initially cloned by complementation
of a yeast mutant auxotrophic for inositol,
which was known to be essential for
ER expansion. Thus, this observation
highlighted the connection between the
UPR and the expansion of the ER that
was a postulated prerequisite for its
upregulation.
Both groups speculated that Ire1p
would function in the ER similarly to how
other transmembrane kinases functiontember 11, 2014 ª2014 Elsevier Inc. 1221
Peter Walter and Kazutoshi Mori, winners of the 2014 Albert Lasker
Basic Medical Research Awardin the plasma membrane,
specifically that its N-terminal
domain would be localized in
the lumen of the ER. There, it
could sense unfolded pro-
teins, perhaps via interactions
with BiP, and would transmit
that signal to the cytoplasmic
kinase domain. The kinase
domain would then phos-
phorylate downstream pro-
tein(s), thereby transmitting
the signal to the nucleus,
where the transcription of
various genes encoding pro-
teins important for the UPR
could be activated. Due to
the contiguous nature of the
nuclear membrane and the
ER, it was also postulated
that Ire1p is positioned withits kinase domain in the nucleus. Although
the general ideas put forth in Walter’s and
Mori’s initial reports would prove to be
true, the molecular mechanism used by
Ire1p to transmit the signal to the nucleus
is decidedly unconventional. In fact, this
mechanism would prove to be so unex-
pected that unraveling it required return-
ing to the early stages of their work in
order to characterize and understand
the transcription factor that binds to the
UPRE.
Still in step, Walter and Mori (now at the
HSP Research Institute in Kyoto, Japan)
independently identified Ern4p/Hac1p as
the transcription factor that controlled
the UPR. Both groups recognized that
Hac1p binds to the UPRE and activates
the transcription of genes involved in ER
stress. Walter’s group also reported that
the cellular level of Hac1p is regulated
by splicing of itsmRNA in an Ire1p-depen-
dent fashion (Cox and Walter, 1996; Mori
et al., 1996). They went on to show that
Hac1p translated from spliced mRNA
(encoding Hac1pi) differs from the protein
encoded by unspliced mRNA (encoding
Hac1pu) in that Hac1pi accumulates in
cells to attain a concentration sufficient
to activate transcription of its target
genes. They also noted that the splice
junctions of HAC1 mRNA do not conform
to the consensus of spliceosome-
mediated splicing and that splicing is
not blocked in spliceosome-defective
mutants. This unique nonconventional
splicing is the first example of splicing as1222 Cell 158, September 11, 2014 ª2014 Elan obligatory regulatory step in a signal
transduction pathway and resulted in a
paradigm shift in our thinking about RNA
splicing. Mori’s group confirmed these
results and made a critical discovery that
the absence of Hac1p in unstressed cells
is not due to differences in protein or
mRNA stability but, rather, is due to a
lack of translation (Kawahara et al.,
1997). Collectively, these observations
launched the next round of investigations
focused on this unusual regulatory mRNA
splicing.
Ire1’s Surprising Mechanism
Walter and colleagues took a closer look
at bioinformatic information, which sug-
gested that Ire1p’s C terminus closely
resembles RNase L, as both proteins
harbored a kinase domain and a nuclease
domain (Sidrauski and Walter, 1997).
They expressed the cytoplasmic/nuclear
portion of Ire1p as a fusion protein with
glutathione S transferase in E. coli. The
fusion protein has an active kinase
domain that cleaves HAC1u RNA gener-
ated by in vitro transcription. Notably,
the RNase activity of Ire1p could be
functionally separated from the kinase ac-
tivity because ADP and nonhydrolyzable
ATP analogs could substitute for ATP in
the reaction mixture. Finally, by adding
tRNA ligase, the splicing of HAC1 mRNA
could be recapitulated in vitro. Walter’s
laboratory proceeded to use their in vitro
system to biochemically characterize
this nonconventional splicing reactionsevier Inc.and found that the mecha-
nism resembles pre-tRNA
splicing. Specifically, the en-
donucleolytic cleavage leaves
20,30-cyclic phosphates and
the excised exon remain
associated by base pairing.
This is then followed by exon
ligation by tRNA ligase. This
type of processing was here-
tofore unknown for mRNAs.
But the novelty of the story
did not stop there. Walter
and Chapman went on to
demonstrate that HAC1u
mRNA was indeed trans-
ported from the nucleus into
the cytoplasm, where it asso-
ciated with polyribosomes
in an unproductive manner.
The presence of the intronattenuated mRNA translation not only in
the context of its own RNA, but also
when it was spliced to the 30 untranslated
region of a heterologous RNA. This
was the first report of a new mechanism
by which RNA translation could be
controlled.
Branching Out
Up until the late 1990s, Walter’s and
Mori’s groundbreaking work had been
carried out in S. cerevisiae. Whether
metazoans would use a conserved sys-
tem to initiate their UPR remained an
open question. Enter Randal Kaufman
and David Ron, whose groups indepen-
dently tackled this problem using classic
bioinformatics and molecular biology
techniques to clone mammalian Ire1p.
They concluded that human Ire1p is an
essential proximal sensor of the UPR in
mammalian cells and functions much
like yeast Ire1p. Ron’s laboratory also
showed that human Ire1p upregulates
the expression of the CHOP/GADD153
(CCAAT/enhancer binding protein homol-
ogous protein/growth arrest DNA damage
153) gene. This was in agreement with
prior data demonstrating not only that
ER stress upregulates ER resident pro-
teins and chaperones, but also that
chronic ER stress is linked to pro-
grammed cell death, a situation in which
CHOP played a predominant role. By the
end of the 20th century, Ire1 and the
molecular mechanism by which it func-
tioned in UPR were known to be highly
conserved between yeast and mammals,
and the details of its mechanism of action
were falling into place. But, what was the
mammalian equivalent of HAC1? This
was a challenging question that would
only be answered after a detour into other
components of the UPR.
First, the UPR in metazoans was to
becomemore complicated. Ire1p is solely
responsible for the UPR in yeast, but
higher organisms have multiple mecha-
nisms in place to fine-tune this important
cell biology problem. It had long been
known that protein synthesis and correct
folding of ER resident and secreted pro-
teins is modulated under stress condi-
tions by phosphorylation of eIF-2a. Phos-
phorylated eIF-2a attenuates protein
translation, presumably lessening the ER
burden. In keeping with the coincident
publication standard set by Walter and
Mori, Ronald Wek and David Ron discov-
ered a new kinase involved in ER stress
that phosphorylates eIF-2a on Ser-51
(Harding et al., 1999; Shi et al., 1998).
Their publications appeared a month
apart, with their chosen names for the ki-
nase differing by only one letter, PEK
versus PERK, respectively. The PERK
catalytic domain is related to eIF-2a
kinases, and PERK kinase activity simi-
larly results in downregulation of protein
translation. Unlike other eIF-2a kinases,
PERK contains a signal peptide destining
it for integration into the ER membrane.
PERK’s domain architecture is similar to
Ire1 without the nuclease domain. This
arrangement placed the kinase domain
in the cytoplasm, where it phosphorylates
its target, eIF-2a. Cellular conditions that
result in the phosphorylation of eIF-2a
include but are not limited to starvation
of amino acids, glucose, or serum, as
well as growth factor deprivation, heat
shock, and unfolded proteins. Presum-
ably, the N-terminal domain of PERK
senses one or more of these conditions
in the ER and increases its kinase activity,
resulting in preferentially reduced transla-
tion of proteins destined for the secretory
pathway.
Concordantly, Mori’s laboratory dis-
covered a third member of the UPR triad,
ATF6 (activating transcription factor 6)
(Yoshida et al., 1998). In yeast, the UPRE
was originally defined as a cis-acting
DNA element specified by the partially
palindromic sequence CAGCGTG that isnecessary and sufficient for induction of
the KAR2 gene encoding yeast GRP78/
BiP. Similarly, the mammalian UPR can
be largely specified by the unique
sequence CCAAT-N9-CCACG. This cis-
acting element is designated the ER
stress response element (ERSE), and it
is necessary and sufficient for the induc-
tion of at least three ER chaperones.
Mori’s group used this sequence in a
yeast one-hybrid screen for DNA-binding
proteins and obtained the bZIP (basic
leucine zipper domain) protein ATF6.
ATF6 is a constitutively expressed
90 kDa protein that is embedded in the
ER but is converted to a 50 kDa nuclear-
localized protein upon ER stress. ATF6 is
a type II transmembrane glycoprotein
with the hydrophobic membrane span-
ning amino acids located in the middle
of the molecule. The N-terminal half con-
tains a basic leucine zipper motif that
resides in the cytoplasm, whereas the
C-terminal domain is localized within the
lumen and presumably senses ER stress.
ER stress induces transport to the Golgi
apparatus, and proteolysis releases the
cytoplasmic domain, which translocates
into the nucleus and, in cooperation with
the general transcription factor NF-Y,
activates transcription of the endogenous
BiP gene among other targets. This
mechanism of action is eerily similar to
that reported for cholesterol homeostasis,
wherein depletion of sterols results in the
cleavage of SREBPs, thus permitting the
transfer of the N-terminal transcription
factor to the nucleus, where it enhances
transcription of target genes involved in
cholesterol homeostasis.
The work described above defined
the major triad of the UPR and began to
define themolecular machines it employs.
Yet, there were still many questions to be
answered, in particular, what was the
mammalian equivalent of HAC1?
2000 and Beyond
As was mentioned previously, mam-
malian Ire1 had been characterized and
was shown to be similar to yeast Ire1p
in its domain architecture and enzymatic
properties. However, no mammalian
HAC1 counterpart had been identified.
While looking into ATF6 targets, Mori’s
group identified the long-sought tran-
scription factor XBP1 (Yoshida et al.,
2001). Like HAC1, XBP1mRNA is splicedCell 158, Sepby IRE1, and only the protein translated
from the spliced mRNA form could
activate the UPR effectively. XBP1 had
been difficult to find because it shares
essentially no sequence identity at the
nucleotide or amino acid level with
Hac1. However, it is a bZIP protein like
ATF6 though it binds DNA markedly
differently, thereby inducing a different
set of target genes. Working with Mori’s
group, Kaufman and his colleagues char-
acterized the UPR response in C. elegans
and demonstrated that it consists of both
the ire-1 and pek-1 branches. Using the
XBP1 amino acid sequence reported by
Mori’s group, they found the C. elegans
XBP1 ortholog, which is a bZIP protein
that surprisingly shares no amino acid ho-
mology with human XBP1 or yeast Hac1p
except within the bZIP region (Shen et al.,
2001). However, its mRNA is spliced by
IRE1, thus preserving the general regula-
tory mechanism defined by HAC1 mRNA
splicing in yeast. Working independently,
Ron’s laboratory also characterized the
UPR in C. elegans. Using an elegant ge-
netic screen, they identified XBP1 and
confirmed that IRE1-mediated process-
ing of XBP1 mRNA is conserved (Calfon
et al., 2002).
Although we have a good mechanistic
understanding of how the UPR functions,
there were still perplexing questions that
await resolution. For example, does IRE1
phosphorylate a protein target other
than itself, and is autophosphorylation
necessary for the UPR? In collaboration
with Kevan Shokat, Walter’s group (Papa
et al., 2003) mutated the Ire1 kinase
domain such that it becomes an ATP
competitive inhibitor. Unexpectedly, the
drug-sensitized Ire1p still induces a
full UPR, indicating that conformational
changes within the kinase domain are
induced by occupancy of the active site
with ligand and not that phosphorylation
per se activates downstream functions.
Indeed, structural studies by Robert
Stroud and Walter on a drug-activated
Ire1p have shown that it oligomerizes
into a rod-shaped assembly heretofore
unseen among kinases. Structural studies
on the N-terminal domain demonstrated
that it also oligomerizes, forming a
deep groove architecturally similar to the
binding pockets that occur in the pep-
tide-binding domain of the major histo-
compatibility complex (MHC). Becausetember 11, 2014 ª2014 Elsevier Inc. 1223
these domains in the MHC bind directly
to unstructured peptides, it has been
proposed by analogy that the groove in
Ire1 also binds unfolded proteins in the
ER (Gardner and Walter, 2011). These
structural studies are critical to the
design of drugs to combat UPR-associ-
ated diseases.
Concluding Remarks
The unfolding of this story eloquently
exposes the molecular mechanisms
responsible for the complex cell biology
problem known as the UPR. The inability
of cells to deal with misfolded proteins
is now recognized as the underpinning
for many human diseases. Examples of
diseases that can be defined by protein
misfolding or ER overload include retinitis
pigmentosa and type II diabetes. Even
some types of cancer subvert the cyto-
protective role of the UPR to maintain
rapid growth. One hope is that future
efforts to treat these diseases will be
facilitated by a better mechanistic and1224 Cell 158, September 11, 2014 ª2014 Elstructural understanding of the UPR. We
congratulate this year’s Lasker Basic
Medical Research Award recipients
on their remarkable discoveries and
astounding progress. Undoubtedly, the
future harbors many interesting and
unforeseen plots yet to unfold.
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